Merit Medical Announces Appointment of Two New Directors
January 03 2019 - 9:25AM
Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer
and marketer of proprietary disposable devices used in
interventional, diagnostic and therapeutic procedures, particularly
in cardiology, radiology, oncology, critical care and endoscopy,
today announced that its Board of Directors increased the number of
directors of the Company from nine to eleven and elected Jill
Anderson and Elizabeth Huebner to fill the new Board positions,
effective January 1, 2019.
Anderson co-founded Cianna Medical, Inc. in 2008
and served as Chief Executive Officer until Merit acquired Cianna
in November 2018. She led Cianna through several financings to
support the development and commercialization of market-leading,
transformative technologies in breast cancer treatment and surgery.
Prior to Cianna, Anderson served as President of BioLucent, Inc., a
privately-held medical device company, from 2001 to 2007. She also
served as Vice President, Oncology Services, for Lehigh Valley
Hospital and Health Network, a teaching hospital and
multi-healthcare network in northeastern Pennsylvania. Anderson has
served on the Board of Directors for Cianna, Mammoplan LLC, and
Solis Women’s Health.
Huebner served as a director of Blucora, a
financial technology company focused on providing online tax
preparation and wealth management products, where she served as
chair of the Audit and Nominating & Corporate Governance
Committees and a member of the Compensation Committee. She held
multiple executive finance positions at several companies before
retiring in 2006 when she served as Senior Vice President and Chief
Financial Officer for Getty Images, Inc., a stock photography
company.
“We are pleased to have two new directors join
our Board,” said Fred P. Lampropoulos, Merit’s Chairman and Chief
Executive Officer. “We believe Anderson, with her years of
leadership and experience in the medical device industry,
particularly in women’s health and oncology, will be a great
addition. We believe Huebner’s years of leadership and experience
in accounting, financial management and analysis, will be very
beneficial as well.”
ABOUT MERITFounded in 1987, Merit Medical
Systems, Inc. is engaged in the development, manufacture and
distribution of proprietary disposable medical devices used in
interventional, diagnostic and therapeutic procedures, particularly
in cardiology, radiology, oncology, critical care and
endoscopy. Merit serves client hospitals worldwide with a
domestic and international sales force and clinical support team
totaling in excess of 300 individuals. Merit employs
approximately 5,600 people worldwide with facilities in South
Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern,
Pennsylvania; Rockland, Massachusetts; San Jose and Aliso Viejo,
California; Maastricht and Venlo, The Netherlands; Paris, France;
Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville,
Brazil; Markham, Ontario, Canada; Melbourne, Australia; Tokyo,
Japan; and Singapore.
FORWARD-LOOKING STATEMENTSStatements contained
in this release which are not purely historical are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and are subject to risks and uncertainties such
as those described in Merit's Annual Report on Form 10-K for the
year ended December 31, 2017 and subsequent filings with the
Securities and Exchange Commission. Such risks and
uncertainties include risks relating to Merit's potential inability
to successfully manage growth through acquisitions, including the
inability to commercialize technology acquired through completed,
proposed or future transactions; expenditures relating to research,
development, testing and regulatory approval or clearance of
Merit's products and risks that such products may not be developed
successfully or approved for commercial use; governmental scrutiny
and regulation of the medical device industry, including
governmental inquiries, investigations and proceedings involving
Merit the potential of fines, penalties or other adverse
consequences if Merit's employees or agents violate the U.S.
Foreign Corrupt Practices Act or other laws or regulations; laws
and regulations targeting fraud and abuse in the healthcare
industry; potential for significant adverse changes in governing
regulations; changes in tax laws and regulations in the United
States or other countries; increases in the prices of commodity
components; negative changes in economic and industry conditions in
the United States or other countries; termination or interruption
of relationships with Merit's suppliers, or failure of such
suppliers to perform; the effects of fluctuations in exchange rates
on projected financial results; development of new products and
technology that could render Merit's products obsolete; changes in
healthcare policies or markets related to healthcare reform
initiatives; failure to comply with applicable environmental laws;
changes in key personnel; work stoppage or transportation risks;
price and product competition; availability of labor and materials;
fluctuations in and obsolescence of inventory; and other factors
referred to in Merit's Annual Report on Form 10-K for the year
ended December 31, 2017 and other materials filed with the
Securities and Exchange Commission. All subsequent forward-looking
statements attributable to Merit or persons acting on its behalf
are expressly qualified in their entirety by these cautionary
statements. Actual results will likely differ, and may differ
materially, from anticipated results. Financial estimates are
subject to change and are not intended to be relied upon as
predictions of future operating results, and Merit assumes no
obligation to update or disclose revisions to those estimates.
Contact:Phone: |
|
Anne-Marie
Wright, Vice President, Corporate Communications(801)
208-4167 e-mail: awright@merit.com Fax: (801)
253-1688 |
|
|
|
Merit Medical Systems (NASDAQ:MMSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merit Medical Systems (NASDAQ:MMSI)
Historical Stock Chart
From Sep 2023 to Sep 2024